30 minutes
While the barriers to treatment and care are typically higher for rare diseases, they are even higher for people of color living with rare diseases. These disparities often start to take shape during the clinical research process for rare diseases, where racial and ethnic minorities are chronically underrepresented. During this panel, leaders in the biotech, pharma, and advocacy communities will examine the current state of rare disease research and discuss how the sector can counter longstanding health inequities.


Chrystal Louis, MD, MPH - Vice President, Head of Medical Affairs, CRISPR Therapeutics
Desiree Jones-Devonish - Sr. Director Clinical Operations, Biogen
Heather Dean - Vice President, Hematology Franchise Head
Shamonica Wiggins - Sickle Cell Patient & Social Media Manager, Sickle Cell Community Consortium